Jana Havrankova, MD; Raymond Lahaie, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editors: Sucralfate is widely used in gastrointestinal ulcer therapy and as a cytoprotective agent in patients receiving anti-inflammatory agents. Because prevalence of hypothyroidism varies from 0.5% to 4%, physicians may see patients who have been treated with both levothyroxine and sucralfate. We examined a 63-year-old woman taking sucralfate, whose hypothyroidism (secondary to radioiodine treatment for diffuse toxic goiter given 8 months earlier) could not be corrected despite administration of up to 4.8 µg/kg body weight of levothyroxine, three times the usual replacement dose. When levothyroxine was taken 2.5 hours after sucralfate, the plasma thyroid-stimulating hormone (TSH) level remained
Havrankova J, Lahaie R. Levothyroxine Binding by Sucralfate. Ann Intern Med. 1992;117:445–446. doi: 10.7326/0003-4819-117-5-445_3
Download citation file:
Published: Ann Intern Med. 1992;117(5):445-446.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use